Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

Abstract:

PURPOSE:Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast cancer incidence among young women in the United States. METHODS:Using 2004-2013 National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program data, we calculated breast cancer incidence rates and trends and examined variations in stage, grade, and tumor subtype by age and race/ethnicity among young women aged 20-49 years. RESULTS:The majority of breast cancer cases occurred in women aged 40-44 and 45-49 years (77.3%). Among women aged < 45 years, breast cancer incidence was highest among black women. Incidence trends increased from 2004 to 2013 for Asian or Pacific Islander (API) women and white women aged 20-34 years. Black, American Indian or Alaska Native, and Hispanic women had higher proportions of cases diagnosed at later stages than white and API women. Black women had a higher proportion of grade III-IV tumors than other racial/ethnic groups. Across all age groups, incidence rates for triple-negative breast cancer were significantly higher in black women than women of other races/ethnicities, and this disparity increased with age. CONCLUSIONS:Breast cancer among young women is a highly heterogeneous disease. Differences in tumor characteristics by age and race/ethnicity suggest opportunities for further research into personal and cultural factors that may influence breast cancer risk among younger women.

authors

Shoemaker ML,White MC,Wu M,Weir HK,Romieu I

doi

10.1007/s10549-018-4699-9

subject

Has Abstract

pub_date

2018-06-01 00:00:00

pages

595-606

issue

3

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-4699-9

journal_volume

169

pub_type

历史文章,杂志文章
  • Flat epithelial atypia: are we being too aggressive?

    abstract:PURPOSE:The malignant upgrade rate of flat epithelial atypia (FEA) diagnosed on core needle biopsy varies between 0 and 30%. Excision versus observation with radiological follow-up for these lesions remains controversial. We hypothesize that the local rate of FEA is low and that close radiological surveillance is a rea...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05481-9

    authors: DiPasquale A,Silverman S,Farag E,Peiris L

    更新日期:2020-01-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract::The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s10549-009-0560-5

    authors: Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期:2010-06-01 00:00:00

  • Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

    abstract:PURPOSE:The optimal management of breast cancer patients with a positive sentinel lymph node (SLN) who undergo mastectomy remains controversial. This study aimed to describe treatment patterns of patients with positive SLNs who undergo mastectomy using a large population-based database. METHODS:The NCDB was queried fo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05243-7

    authors: Weiss A,Lin H,Babiera GV,Bedrosian I,Shaitelman SF,Shen Y,Kuerer HM,Mittendorf EA,Caudle AS,Hunt KK,Hwang RF

    更新日期:2019-07-01 00:00:00

  • Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil.

    abstract::The contribution of BRCA1 and BRCA2 to breast cancer incidence in Brazil has not yet been explored. In order to estimate the proportion of breast cancers due to BRCA1 and BRCA2 mutations in Brazil, we conducted a study of unselected breast cancer patients from Rio de Janeiro, Brazil. We enrolled 402 women with breast ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9378-6

    authors: Gomes MC,Costa MM,Borojevic R,Monteiro AN,Vieira R,Koifman S,Koifman RJ,Li S,Royer R,Zhang S,Narod SA

    更新日期:2007-07-01 00:00:00

  • A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management.

    abstract:PURPOSE:Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-06009-2

    authors: Shah H,Surujballi J,Awan AA,Hutton B,Arnaout A,Shorr R,Vandermeer L,Alzahrani MJ,Clemons M

    更新日期:2020-11-06 00:00:00

  • Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells.

    abstract::Indole-3-carbinol (I3C) is a promising phytochemical agent in chemoprevention of breast cancer. Our present study is the first description of I3C that significantly inhibits the cell adhesion, spreading and invasion associated with an up-regulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell-...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006495824158

    authors: Meng Q,Goldberg ID,Rosen EM,Fan S

    更新日期:2000-09-01 00:00:00

  • Incidence of invasive breast cancer in the presence of competing mortality: the Canadian National Breast Screening Study.

    abstract::Mortality due to causes other than breast cancer is a potential competing risk which may alter the incidence probability of breast cancer and as such should be taken into account in predictive modelling. We used data from the Canadian National Breast Screening Study (CNBSS), which consist of two randomized controlled ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2113-6

    authors: Taghipour S,Banjevic D,Fernandes J,Miller AB,Montgomery N,Harvey BJ,Jardine AK

    更新日期:2012-07-01 00:00:00

  • Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.

    abstract:PURPOSE:Differences in tumor biology, genomic architecture, and health care delivery patterns contribute to the breast cancer mortality gap between White and Black patients in the US. Although this gap has been well documented in previous literature, it remains uncertain how large the actual effect size of race is for ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05984-w

    authors: Zhao F,Copley B,Niu Q,Liu F,Johnson JA,Sutton T,Khramtsova G,Sveen E,Yoshimatsu TF,Zheng Y,Ibraheem A,Jaskowiak N,Nanda R,Fleming GF,Olopade OI,Huo D

    更新日期:2020-10-27 00:00:00

  • Clinical/genetic features in hereditary breast cancer.

    abstract::Patients from hereditary breast cancer-prone (HBC) families provide one of the most powerful and potentially cost effective models for cancer prevention and control. Paradoxically, this opportunity is often missed in the clinical practice setting due, in part, to inattention to the family history and/or lack of knowle...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01810778

    authors: Lynch HT,Watson P,Conway TA,Lynch JF

    更新日期:1990-02-01 00:00:00

  • Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status.

    abstract::The clinicopathologic, mammographic, and sonographic findings in patients with pure ductal carcinoma in situ (DCIS) were assessed by estrogen receptor (ER) expression. After institutional review board approval, patients with pure DCIS evaluated from January 1996 to July 2009 with known ER status and available imaging ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2598-7

    authors: Rauch GM,Kuerer HM,Scoggins ME,Fox PS,Benveniste AP,Park YM,Lari SA,Hobbs BP,Adrada BE,Krishnamurthy S,Yang WT

    更新日期:2013-06-01 00:00:00

  • Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer: standardization is needed.

    abstract:PURPOSE:Evaluation of the safety and efficacy of a combination of docetaxel and doxorubicin in breast cancer patients. Evaluation and comparison of the pathological complete response (pCR) to this regimen according to various definitions in different clinical trials. Utilize the data to propose standardization of defin...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9889-9

    authors: Mukai H,Watanabe T,Ando M,Shimizu C,Katsumata N

    更新日期:2009-01-01 00:00:00

  • Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

    abstract:PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05479-3

    authors: Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

    更新日期:2020-01-01 00:00:00

  • Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

    abstract::Epidermal growth factor receptor (EGFr) levels were analyzed in 140 primary breast cancer specimens by immunohistochemical assay (ICA), competitive binding assay (BA), or enzyme immunoassay (EIA). Thirty-nine of 118 specimens (33.1%) were scored as positive by ICA, 30 of 116 (25.9%; cut-off level 10 fmol/mg protein) b...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF00666582

    authors: Iwase H,Kobayashi S,Itoh Y,Kuzushima T,Yamashita H,Iwata H,Naito A,Yamashita T,Itoh K,Masaoka A

    更新日期:1993-12-01 00:00:00

  • ErbB-2 protein in sera and tumors of breast cancer patients.

    abstract::We compared levels of erbB-2 oncoprotein among three groups: Group I included 60 asymptomatic women; Group II had 51 women with benign breast biopsies; and Group III had 67 women with node-negative breast cancer. Serological levels of erbB-2 protein were measured in all participants; tumor levels were measured for Gro...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006033214721

    authors: Breuer B,Smith S,Thor A,Edgerton S,Osborne MP,Minick R,Cody HS 3rd,Nowak E,Cortese A,Simmons RM,Carney WP,Brandt-Rauf PW

    更新日期:1998-06-01 00:00:00

  • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.

    abstract:PURPOSE:To evaluate a simplified method of pre-test information and germline BRCA1/2 mutation testing. METHODS:In a prospective, single-arm study, comprehensive BRCA1/2 testing was offered to unselected patients with newly diagnosed breast cancer at three hospitals in south Sweden (BRCAsearch, ClinicalTrials.gov Ident...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-017-4584-y

    authors: Nilsson MP,Törngren T,Henriksson K,Kristoffersson U,Kvist A,Silfverberg B,Borg Å,Loman N

    更新日期:2018-02-01 00:00:00

  • Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.

    abstract:PURPOSE:HER2 gene is a member of the epidermal growth factor receptor (EGFR) family. Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of-function alterations leading to increased receptor signaling. METHODS:We have reviewed the literature currently available on HER2 mutations in huma...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-017-4419-x

    authors: Petrelli F,Tomasello G,Barni S,Lonati V,Passalacqua R,Ghidini M

    更新日期:2017-11-01 00:00:00

  • Factors predicting in-breast tumor recurrence after breast-conserving surgery.

    abstract:PURPOSE:The main objectives of this study were to identify risk factors for local in-breast tumor recurrence after breast-conservation and to evaluate the impact of IBTR (in-breast tumor recurrence) on overall survival. METHODS:A total of 335 consecutive patients with 346 invasive and in situ breast cancers were treat...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-008-0187-y

    authors: Mechera R,Viehl CT,Oertli D

    更新日期:2009-07-01 00:00:00

  • Inherited BRCA2 mutation associated with high grade breast cancer.

    abstract::Inheritance is believed to play a major role in 5-10% of breast cancer. The breast cancer susceptibility genes BRCA1 and BRCA2 are estimated to account for more than half of these cases. Recent studies have suggested that breast cancers associated with BRCA1 germline mutations are of higher grade than sporadic cases. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005853022804

    authors: Agnarsson BA,Jonasson JG,Björnsdottir IB,Barkardottir RB,Egilsson V,Sigurdsson H

    更新日期:1998-01-01 00:00:00

  • Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.

    abstract:PURPOSE:Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits exceptionally effectiv...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05454-y

    authors: Wardell SE,Yllanes AP,Chao CA,Bae Y,Andreano KJ,Desautels TK,Heetderks KA,Blitzer JT,Norris JD,McDonnell DP

    更新日期:2020-01-01 00:00:00

  • Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses.

    abstract::We report the establishment of a breast epithelial cell model that undergoes growth arrest at different stages of the cell cycle depending upon the DNA damaging agents encountered. Primary breast epithelial cells from normal reductive mammoplasty were grown in low-calcium culture medium. Free-floating cells under this...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9173-4

    authors: Shen KC,Miller F,Tait L,Santner SJ,Pauley R,Raz A,Tainsky MA,Brooks SC,Wang YA

    更新日期:2006-08-01 00:00:00

  • A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.

    abstract:PURPOSE:Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with H IV as adjuvant therapy in routine practice. METHODS:The observatio...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5058-6

    authors: Lidbrink E,Chmielowska E,Otremba B,Bouhlel A,Lauer S,Liste Hermoso M,Nüesch E,Shing M,Misra V

    更新日期:2019-02-01 00:00:00

  • Reversed urban-rural differences in breast cancer mortality (China, 2002-2008).

    abstract::The purpose of this study was to examine the urban-rural difference in breast cancer mortality between 2002 and 2008 in China. A longitudinal analysis of mortality data was performed. Mortality data were extracted from Chinese Health Statistics Yearbook. Linear regression was used to examine the statistical significan...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1276-2

    authors: He M,Guo Q,Hu G

    更新日期:2011-02-01 00:00:00

  • The prognostic value of NRF2 in breast cancer patients: a systematic review with meta-analysis.

    abstract:PURPOSE:Nuclear factor E2-related factor 2 (NRF2) is a transcription factor that plays a major role in the regulation of intracellular antioxidant response. The effect of NRF2 overexpression in many malignancies is still unclear and recent meta-analysis correlated NRF2 overexpression with poor prognosis in a variety of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-019-05494-4

    authors: Almeida M,Soares M,Ramalhinho AC,Moutinho JF,Breitenfeld L,Pereira L

    更新日期:2020-02-01 00:00:00

  • Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.

    abstract::Metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. We report results of a neoadjuvant "window of opportunity" study of metformin in women with operable breast cancer. Newly diagnosed, untreated, non-diabetic breast cancer patients received metformin ...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/s10549-012-2223-1

    authors: Niraula S,Dowling RJ,Ennis M,Chang MC,Done SJ,Hood N,Escallon J,Leong WL,McCready DR,Reedijk M,Stambolic V,Goodwin PJ

    更新日期:2012-10-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract::The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014815112078

    authors: Hayden LJ,Satre MA

    更新日期:2002-03-01 00:00:00

  • Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?

    abstract:PURPOSE:We sought to determine if bioimpedance spectroscopy (BIS) measurements can accurately assess changes in breast cancer-related lymphedema (BCRL) in patients undergoing lymphovenous bypass (LVB). METHODS:Patients undergoing LVB for BCRL refractory to conservative treatment from 1/2015 to 12/2018 were identified ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-06059-6

    authors: Sutherland A,Wagner JL,Korentager S,Butterworth J,Amin AL,Balanoff CR,Hangge A,Larson KE

    更新日期:2021-01-04 00:00:00

  • Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.

    abstract:BACKGROUND:Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia. In the literature, differ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9880-5

    authors: Caliskan M,Gatti G,Sosnovskikh I,Rotmensz N,Botteri E,Musmeci S,Rosali dos Santos G,Viale G,Luini A

    更新日期:2008-12-01 00:00:00

  • Sealing of postoperative axillary leakage after axillary lymphadenectomy using a fibrin glue coated collagen patch: a prospective randomised study.

    abstract::Seroma formation after axillary lymphadenectomy in women with breast cancer remains a problem despite many efforts to reduce surgery-related morbidity. In a prospective, randomised, open, parallel-group, controlled clinical trial we evaluated the effect of a fibrin-glue coated collagen patch (TachoComb H, Nycomed Phar...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1010671209279

    authors: Berger A,Tempfer C,Hartmann B,Kornprat P,Rossmann A,Neuwirth G,Tulusan A,Kubista E

    更新日期:2001-05-01 00:00:00

  • Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors.

    abstract::Treatment decisions in oncology are based on a balance between the efficacy of therapy and its side effects. Patients with metastases and patients with a limited prognosis are a particular challenge, since communication about the disease situation and the expected therapeutic benefit is difficult not only for patients...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2557-3

    authors: Lux MP,Bayer CM,Loehberg CR,Fasching PA,Schrauder MG,Bani MR,Häberle L,Engel A,Heusinger K,Tänzer T,Radosavac D,Scharl A,Bauerfeind I,Gesslein J,Schulte H,Overbeck-Schulte B,Beckmann MW,Hein A

    更新日期:2013-06-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract::A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1023081624133

    authors: Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期:2003-04-01 00:00:00